Table 1.

Eligibility criteria of included studies

Population	Women with HER2-positive breast cancer
Intervention	Neoadjuvant or adjuvant treatment with subcutaneous trastuzumab
Control	Neoadjuvant or adjuvant treatment with intravenous trastuzumab
Outcomes	• Efficacy (overall survival, event-free survival) • Safety: overall risk of adverse events, serious adverse events, discontinuation because of adverse events • Patients’ preferences
Study design	RCTs, systematic reviews, and meta-analyses

HER human epidermal growth factor receptor, RCT randomized controlled trial